Research map: Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis

Back to the article

Papers in this map

  1. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance · Norah A. Terrault · 2018 · 4395 citations · Cited by this paper
  2. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial · ZhiCheng Lai · 2022 · 158 citations · Cites this paper
  3. HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · 2026 · Related
  4. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial · Anthony B. El-Khoueiry · 2017 · 4384 citations · Cited by this paper
  5. KASL clinical practice guidelines for management of chronic hepatitis B · 2022 · 130 citations · Cites this paper
  6. Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · 2026 · Related
  7. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial · Richard S. Finn · 2019 · 1842 citations · Cited by this paper
  8. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis · Zhengzheng Xia · 2023 · 33 citations · Cites this paper
  9. Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · 2026 · Related
  10. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion · Minke He · 2019 · 565 citations · Cited by this paper
  11. Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy · Xuanye Zhang · 2021 · 29 citations · Cites this paper
  12. Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · 2026 · Related
  13. Untitled · Cited by this paper
  14. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis · Zi‐Niu Ding · 2022 · 27 citations · Cites this paper
  15. Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · 2026 · Related
  16. Untitled · Cited by this paper
  17. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors · Lei Jin · 2022 · 25 citations · Cites this paper
  18. Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · 2026 · Related
  19. Untitled · Cited by this paper
  20. HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors · Jiaming Shen · 2023 · 23 citations · Cites this paper
  21. Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · 2026 · Related
  22. Untitled · Cited by this paper
  23. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis · Xiaoyun Hu · 2022 · 18 citations · Cites this paper
  24. Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study · 2026 · Related
  25. Untitled · Cited by this paper
  26. Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review · Jian Zhao · 2022 · 16 citations · Cites this paper
  27. Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis · 2026 · Related
  28. Untitled · Cited by this paper
  29. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors · Khalis Mustafayev · 2024 · 15 citations · Cites this paper
  30. Untitled · Cited by this paper
  31. 5-FU promotes HBV replication through oxidative stress-induced autophagy dysfunction · Jing Yang · 2024 · 13 citations · Cites this paper
  32. Untitled · Cited by this paper
  33. Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma · Kehui Liu · 2022 · 12 citations · Cites this paper
  34. Untitled · Cited by this paper
  35. The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB · Shike Lou · 2023 · 12 citations · Cites this paper
  36. Untitled · Cited by this paper
  37. Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer · Jie Zhou · 2023 · 9 citations · Cites this paper
  38. Untitled · Cited by this paper
  39. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy · Yingfu Zeng · 2024 · 9 citations · Cites this paper

Source: OpenAlex (CC0)